You Position: Home > Paper
Meta-analysis of safety and efficacy of S-1-based regimens in treatment of metastatic colorectal cancer
( views:26, downloads:0 )
- Author:
- No author available
- Journal Title:
- World Chinese Journal of Digestology
- Issue:
- 22
- DOI:
- 10.11569/wcjd.v27.i22.1375
- Key Word:
- 结直肠癌;S-1;FOLFOX4;FOLFIRI;Meta分析
Abstract： 背景近年来,有研究发现口服S-1方案较静脉注射FOLFOX4/FOLFIRI方案治疗转移性结直肠癌(metastatic colorectal cancer,mCRC)具有比较好的疗效.本研究旨在运用Meta分析的研究方法系统性评价口服S-1方案在治疗mCRC中的治疗效果和安全性,进而提供循证医学相关的依据.目的运用Meta分析的研究方法系统性评价口服S-1方案在治疗mCRC中的治疗效果和安全性.方法检索口服S-1方案治疗mCRC的对照试验,时间范围2009-01/2019-01,以Cochrane系统评价手册所制定的评价标准对于所选择的文献进行系统评价,检索的数据库包括:维普数据库、万方数据库、中国生物医学文献数据库、中国知网数据库、The Cochrane Library、PubMed、Embase,用Revman 5.3软件对于所筛选的文献进行Meta分析,以95％可信区间估计.结果Meta分析结果表明:实验组患者在3年总生存率和3年无瘤生存率方面的生存率高于对照组,差异有统计学意义(OR=0.65,95％CI:0.47,0.89,P=0.008)、(OR=1.45,95％CI:1.03,2.06,P=0.04).实验组患者在总不良反应方面的发生率低于对照组患者,二者差异有统计学意义(OR=0.68,95％CI:0.53,0.87,P=0.002),在骨髓抑制、脱发、恶心呕吐、皮肤反应发生率均低于对照组,二者差异有统计学意义(P＜0.05).结论口服S-1方案较静脉注射FOLFOX4/FOLFIR方案治疗mCRC的效果好且不良反应少、安全性较高.
- [1]洪立立,郭志,于海鹏,等.低功率高强度聚焦超声联合 SOX 方案治疗结直肠癌伴盆腔转移[J].2014,(25).
- [2]Atsuo, Imagawa,Satoshi, Okumura,Sho, Toyoda,etc.[A Case of Metastatic Carcinoma of Anal Fistula].[J].2018,45(1).
- [3]Molina Garrido MJ,Guillen Ponce C.Letter to the editor: "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer".[J].2011,29(6).
- [4]Kazuaki, Harada,Kazuteru, Hatanaka,Kenji, Kinoshita,etc.[Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as first-line treatment-a case report].[J].2014,41(7).
- [5]Narikazu Boku,Seiichiro Yamamoto,Haruhiko Fukuda,etc.Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study[J].2009,10(11).
- [6]Satoshi, Nagase,Tomokazu, Iyoda,Hiroshi, Kanno,etc.[Comparison of the Cost-Effectiveness of the SOX and COX Regimens in Patients with Unresectable Advanced and Recurrent Colorectal Cancer Using a Clinical Decision Analysis Approach].[J].2016,(10).
- [7]Shu, Okamura,Kohei, Murata,Yuma, Wada,etc.[A case of peritoneal dissemination that exhibited a complete response to systemic chemotherapy following the resection of primary colon cancer].[J].2012,39(12).
- [8]Yamakawa K,Imaida K,Kuno T,etc.Overexpression of CYP2A6 in human colorectal tumors.[J].2007,98(10).
- [9]Kenta,Tominaga,Yasuhiro,Kurumiya,Ei,Sekoguchi,etc.[Severe Liver Injury Due to Sinusoidal Obstruction Syndrome Induced by Oxaliplatin in a Patient with Resectable Colorectal Liver Metastases].[J].2018,45(6).
- [10]Yoshida, M.,Muro, K.,Tsuji, A.,etc.Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)[J].2015,51(8).
- [11]Ming, Bai,Ting, Deng,Rubing, Han,etc.Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial.[J].2015,8.
- [12]Ryota,Koyama,Yoshiaki,Maeda,Nozomi,Minagawa,etc.Laparoscopic Resection of an Abdominal Wall Metastasis 5 Years after Primary Colorectal Cancer Resection.[J].2019,13(1).